New Retina Radio
New Retina Radio

02.11.22

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

View full description +

MORE EPISODES

10.10.25

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care

Niki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

10.09.25

The Nuts and Bolts of GA Therapy: The Opening Sessions

Charles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

09.26.25

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

Show More